July 21, 2026 08:00 AM GMT China Pharmaceuticals | Asia Pacific M Idea 1H26 Earnings Preview: BD Outlook Outshining Transient Domestic Disruption Valuation remains well supported by robust business development (BD) outlook and manageable domestic policy impact, in our view. We preview 1H26 earnings, partner execution progress of announced BD deals and new deal outlook, key clinical readouts, and other major catalysts into 2H26. Key Takeaways With this report, Alexis Yan assumes primary coverage of Nanjing L ...